UPLIFT (ENGOT-ov67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin, a NaPi2b-directed dolaflexin antibody-drug conjugate, in platinum-resistant ovarian cancer

被引：0

作者：

Richardson, Debra ^{[1
]}

Iyer, Gopa ^{[2
]}

Schmid, Anita ^{[3
]}

Palma, Norma ^{[3
]}

Navarro, Willis ^{[3
]}

Ahnert, Jordi Rodon ^{[4
]}

机构：

[1] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Aadi Biosci, Pacific Palisades, CA USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 190卷

关键词：

D O I：

10.1016/j.ygyno.2024.07.424

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2126

引用

页码：S285 / S286

页数：2

共 23 条

[1] UPLIFT (ENGOT-OV67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer
Richardson, Debra
Concin, Nicole
Hays, John
Perez Fidalgo, Jose Alejandro
Pothuri, Bhavana
Banerjee, Susana
Ghamande, Sharad
Ray Coquard, Isabelle
Germanova, Anna
Rimel, Bobbie
Lorusso, Domenica
Cloven, Noelle
Baurain, Jean-Francois
Randall, Leslie
Brasiuniene, Birute
Tseng, Jill
Klasa-Mazurkiewicz, Dagmara
Werner, Theresa
Oaknin, Ana
Ang, Joo Ern
Leary, Alexandra
Bishop, Erin
Marth, Christian
Bradshaw, Chelsea
Burger, Robert
Gonzalez Martin, Antonio Jose
GYNECOLOGIC ONCOLOGY, 2024, 190 : S56 - S56
[2] UPLIFT (ENGOT-OV67/GOG-3048) A PIVOTAL COHORT OF UPIFITAMAB RILSODOTIN, A NAPI2B-DIRECTED ADC IN PLATINUM-RESISTANT OVARIAN CANCER
Concin, N.
Hamilton, E.
Randall, L. M.
Banerjee, S.
Mileshkin, L.
Coleman, R. L.
Monk, B.
Mirza, M. R.
Savarese, A.
Ray-Coquard, I.
Perez Fidalgo, J. A.
Bernardo, P.
Putiri, E.
Burger, R.
Mosher, R.
Richardson, D.
Cibula, D.
Madry, R.
Chekerov, R.
Van Gorp, T.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A205 - A205
[3] UPLIFT (ENGOT-OV67/GOG-3048) A PIVOTAL COHORT OF THE XMT-1536-1 TRIAL OF UPIFITAMAB RILSODOTIN (XMT-1536; UPRI), A NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) IN PLATINUM-RESISTANT OVARIAN CANCER
Richardson, Debra
Perez Fidalgo, Jose Alejandro
Gonzalez-Martin, Antonio
Oaknin, Ana
Hamilton, Erika
Hays, John
Pothuri, Bhavana
Papadopoulos, Kyriakos
Taylor, Sara
Huang, Marilyn
Lee, Yeh-Chen
Krivak, Thomas
Moreno-Garcia, Victor
Calvo, Emiliano
Randall, Leslie
Starks, David
Ross, Malcom
Duska, Linda
Gao, Bo
Poka, Robert
Putiri, Emily
Barrett, Jamie
Demars, Leslie
Concin, Nicole
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A241 - A241
[4] Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.
Richardson, Debra L.
Hamilton, Erika P.
Oaknin, Ana
Randall, Leslie M.
Banerjee, Susana N.
Taylor, Sara Kristina
Mileshkin, Linda R.
Coleman, Robert L.
Monk, Bradley J.
Mirza, Mansoor Raza
Bernardo, Patricia
Mosher, Rebecca
Jansen, Valerie Malyvanh
Savarese, Antonella
Van Gorp, Toon
Madry, Radoslaw
Ray-Coquard, Isabelle Laure
Concin, Nicole
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer
Richardson, Debra
Hamilton, Erika
Barve, Minal
Anderson, Charles
Taylor, Sara
Lakhani, Nehal
Buscema, Joseph
Tolcher, Anthony
Zarwan, Corrine
Werner, Theresa
Hays, John
Arend, Rebecca
Edenfield, Jeffery
Putiri, Emily
Bernardo, Patricia
Burger, Robert
Matulonis, Ursula
GYNECOLOGIC ONCOLOGY, 2022, 166 : S48 - S48
[6] Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer
Lakhani, Nehal
Burns, Timothy
Barve, Minal
Edenfield, Jeffery
Hays, John
Zarwan, Corrine
Werner, Theresa
Anderson, Charles
Buscema, Joseph
Bernardo, Patricia
Keeton, Erika
Carrington, Cassandra
Burger, Robert
GYNECOLOGIC ONCOLOGY, 2022, 166 : S285 - S286
[7] UP-NEXT (GOG-3049/ENGOT-OV71-NSGO-CTU): A STUDY OF UPIFITAMAB RILSODOTIN (UPRI), A NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER
Richardson, Debra
Harter, Philipp
O'Malley, David
Gonzalez-Martin, Antonio
Herzog, Thomas
Rogalski, Caroline
Burger, Robert
Mirza, Mansoor
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A241 - A241
[8] UPGRADE: PHASE 1 COMBINATION TRIAL OF THE NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) IN PATIENTS WITH OVARIAN CANCER
Hays, John
Werner, Theresa
Lakhani, Nehal
Edenfield, Jeffrey
Buscema, Joseph
Burns, Timothy
Carrington, Cassandra
Keeton, Erika
Burger, Robert
Anderson, Charles
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A235 - A235
[9] UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of Upitifamab Rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate in platinum-sensitive recurrent ovarian cancer
Richardson, Debra
Harter, Philipp
O'Malley, David
Gonzalez-Martin, Antonio
Herzog, Thomas
Rogalski, Caroline
Burger, Robert
Mirza, Mansoor
GYNECOLOGIC ONCOLOGY, 2023, 176 : S157 - S157
[10] UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer
Richardson, Debra L.
Harter, Philipp
O'Malley, David M.
Martin, Antonio Gonzalez
Herzog, Thomas J.
Rogalski, Caroline
Lemming, Rita
Keeton, Erika
Burger, Robert Allen
Mirza, Mansoor Raza
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 →